Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, “Sun Pharma”)) announces the successful completion of its acquisition of Checkpoint Therapeutics, Inc. (“Checkpoint”), an immunotherapy and targeted oncology company. As part of the acquisition, Sun Pharma acquires UNLOXCYT™, the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma. Sun Pharma has acquired all outstanding shares of Checkpoint at a price of $4.10 per share in cash, without interest, plus one non-tradable contingent value right (CVR) per share.
Read the full article: Sun Pharma Completes Its Acquisition of Checkpoint Therapeutics //
Source: https://www.prnewswire.com/news-releases/sun-pharma-completes-its-acquisition-of-checkpoint-therapeutics-302469542.html